Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer
Modern Pathology, Published online: 07 June 2019; doi:10.1038/s41379-019-0292-yHistological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer
Publication date: Available online 21 August 2019Source: Life SciencesAuthor(s): Chen Shao, Bingbing Yu, Yanan LiuAbstractIn prostate cancer development, the androgen receptor (AR) signaling plays a crucial role during both formation of early prostate lesions and progression to the lethal, incurable castration resistant stage. Accordingly, numerous approaches have been developed to inhibit AR activity including androgen deprivation therapy, application of the AR antagonists as well as the use of taxanes. However, these treatments, although effective initially, resistance inevitably occur for most of the patients within sev...
Publication date: Available online 16 August 2019Source: Inorganica Chimica ActaAuthor(s): Gisele dos S.S. Firmino, Stephanie C. André, Zandora Hastenreiter, Vanessa Karen Campos, Mostafa A.L. Abdel-Salam, Elaine M. de Souza-Fagundes, Josane A. LessaAbstractCancer cells have high iron demand to mediate their rapid proliferation. Aiming to obtain cytotoxic compounds with potential iron metabolism disturbance in malignant cells, [Ga(HAPIH)(APIH)](NO3)2⋅2H2O (1) and [Ga(HPAmIH)(PAmIH)](NO3)2⋅2H2O (2) were synthesized with the iron chelators 2-acetylpyridine- and 2-pyridineformamide isonicotinoyl hydrazone (HA...
Conclusions: The main focus of this review was to understand the interplay between obesity/BMI and UC/PCa. Several pathogenic cellular pathways exploring the issue are discussed, opening the way to challenging tailored treatments on the basis of BMI. Improving the knowledge of molecular connections between obesity and UC and PCa could favor the development of new therapies likely reducing chemo- and immunotherapy drug resistance.
ConclusionsThe results indicate the importance of finding incentives and creating an environment that fosters autonomy, competence and relatedness to motivate persons to exercise during oncological treatment. Some BCTs appear particularly useful and may be used by health professionals to increase patients ’ motivation to exercise.
ConclusionsAdjuvant docetaxel without prednisone did not improve BDFS after radical RT with ADT for intermediate- or high-risk PCa.Patient summaryWe compared six cycles of adjuvant docetaxel given after radical external radiotherapy plus androgen deprivation therapy to surveillance in intermediate- and high-risk localised prostate cancer. We found no overall benefit in this setting.
Publication date: Available online 20 August 2019Source: European UrologyAuthor(s): Alberto Donzelli, Gianluca Castelluzzo, Giulia Giudicatti
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Case Description: A 67-year-old male with history of adenosquamous prostate cancer status post prostatectomy, cystectomy, diverting loop colostomy with urostomy, leuprolide, and radiation was recently started on chemotherapy with docetaxel. He presented to emergency room 3 days after his first docetaxel infusion with complains of fever, nausea, and skin rash in bilateral axillae, and arms. The rash was mildly pruritic and painful. The patient had a recent episode of mild sunburn a week prior to his infusion, which had completely resolved before infusion.
An 82-year-old man with a history of prostate cancer presented with several months of enlarging ulcerated tumors and nodules on the upper and lower extremities. The patient had numerous tumors>7 cm in diameter, including a large grouping of 5-6 on his left anterior thigh, a cobblestone plaque on the right posterior calf, and innumerable discrete nodules on the bilateral forearms. Punch biopsy was performed and revealed a dense dermal nonepidermotropic infiltrate of neoplastic CD3+ CD4+ CD30- T cells with convoluted cerebriform nuclei.
Condition: Prostatic Adenocarcinoma Intervention: Sponsor: University Hospital, Brest Recruiting